|Articles|August 8, 2006

Researchers Find "Secret Weapon" Used by SARS Virus

In 2003, the highly contagious and often-deadly mystery disease now called SARS emerged explosively out of Southern China. It eventually killed an estimated 916 people in Asia, Europe, and North and South Americanearly 1 in 10 of those it infected.

When scientists identified the virus that caused this sudden acute respiratory syndrome, they classified it as a coronavirus--a virus family whose other members cause many common colds. But to there was nothing common about the lethality of SARS; clearly, this coronavirus had some nasty tricks up its sleeve.

Now, in a discovery that suggests a possible new route by which scientists might fashion a vaccine against SARS, researchers at the University of Texas Medical Branch at Galveston (UTMB) have uncovered one of those tricks: a secret weapon that the SARS coronavirus uses to sabotage the immune defenses of infected cells. Experiments conducted by the UTMB scientists show that a SARS coronavirus protein called nsp1 causes the breakdown of biochemical messages that normally prompt the production of a protein critical to defending the body against viruses.

The SARS nsp1 protein degrades the messenger RNA instructions sent from DNA to make interferon beta, which is crucial to host immunity, said UTMB professor of microbiology and immunology Shinji Makino, senior author of a paper on the discovery to be published online the week of August 7 in the Proceedings of the National Academy of Sciences. This is a very rare phenomenon, and it raises a lot of questions among them, whether we can make a mutant form of SARS coronavirus that lacks the ability to degrade messenger RNA, which could ultimately lead to the creation of a live attenuated vaccine for SARS.

Although many viruses interfere with host cells making messenger RNA or translating it into infection-fighting proteins, only one other virus is known to break down messenger RNA: herpes simplex virus (HSV).

Makino credits lead author Wataru Kamitani, a UTMB postdoctoral research fellow, with noticing that the nsp1 protein had an unexpected effect while he was investigating a different set of SARS coronavirus proteins. He found this suppression of host gene expression, and then he designed several elegant experiments that showed it was caused by RNA degradation, something never before seen in an RNA virus.

Exactly how that degradation takes place, how an RNA virus can preserve its integrity when it makes a protein that breaks down RNA, and whether a mutated non-RNA-degrading SARS coronavirus could constitute a workable SARS vaccine are all issues that Makinos group intends to pursue. The main concern for everybody is whether SARS will come back, Makino said. We want to be ready for it if it does.

Source: University of Texas Medical Branch at Galveston

 

 

 

 


Related to this article

Infection preventionists in full PPE with children in DRC.  (Image credit: author with AI)
Nearly 4 months into the DRC's Bundibugyo virus disease outbreak, some indicators suggest transmission may be slowing. But shifting hotspots, treatment-center capacity problems, community deaths, and incomplete surveillance data show why national case totals alone cannot determine whether containment has been achieved.
Health care workers from the US speaking with other health care workers in DRC.  (Image credit: author with AI)
Is the Ebola outbreak in the DRC getting better? The answer depends on which numbers you examine. Several important indicators are moving in the right direction, including slower case growth and a declining Rₜ. But major gaps remain in contact tracing, testing, community deaths, safe burial coverage, and treatment capacity in some of the hardest-hit areas. ICT takes a deeper look at the latest outbreak data and why the numbers suggest cautious optimism, not victory.
Dyan Troxell, MSN, RN, director of clinical education at HandCraft Linen Services; J.J. Odom, MBA, CHESP, CMIP, T-CHEST, university director of buildings and grounds for UConn Health and chair-elect of the AHE Board; and Jenna Rivers, MPH, CPH, CIC, manager of infection prevention and control at Moffitt Cancer Center in Tampa, Florida.
At AHE Exchange 2026, ICT spoke with experts representing commercial laundry services, EVS, and infection prevention about the systems behind a successful reusable linen program. They discuss linen quality, reject rates, unnecessary waste, frontline education, data, PAR levels, infection prevention oversight, and why strong relationships between health care facilities and their laundry providers matter.
A group of students raising their hands in class during a lecture  (Adobe Stock 292282454 by Mediteraneo
How do you celebrate an infection that never happened? That's one of the unusual challenges infection preventionists share with teachers. Both can spend their careers changing outcomes they may never see. Both educate people who don't always want to listen. Both are second-guessed. Both face burnout. And both must somehow keep remembering why they started.